clinicaltrialsarena4h
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial
Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.
RSV vaccines are available for vulnerable adults and the ill. They just can’t afford them.
Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t ...